The use of allogeneic BMT in patients with relapsed non-Hodgkin lymphoma (NHL) offers the advantage of tumor-free bone marrow and possibly a 'graft-versuslymphoma effect' which may decrease the risk of recurrence. However, allogeneic BMT also poses an increased risk of death due to graft-versus-host disease (GVHD) which can be ameliorated by T cell depletion. We performed a retrospective review of 37 patients who underwent T cell-depleted allogeneic BMT for aggressive and indolent NHL between 1988 and 1996. Polymerase chain reaction (PCR) was used to identify indolent NHL patients with the BCL2/IgH translocation which served as a marker of residual disease. Sixteen of 37 patients (44%) are alive and progression-free with a median follow-up of 4.4 years (range 1-10.3). The incidence of grade 2-4 acute GVHD was 36% and extensive chronic GVHD developed in 12%. Patients with aggressive NHL have an overall PFS of 33% (12-54%); those with chemotherapy-resistant and sensitive disease have PFS of 17% (0-47%), and 40% (15-65%) respectively at 5 years. Patients with indolent histologies have overall PFS of 62% (37-86%); those with chemotherapy-resistant and sensitive disease have PFS of 55% (25-85%) and 80% (45-100%) respectively at 5 years. Eight patients with indolent disease had a BCL2/IgH translocation detectable by PCR. Five of these eight patients remain alive and progression free at a median of 6.5 years after BMT (range 2.1-7.4 years), four of whom remain PCR positive from 1.7 to 2.9 years after transplantation. We conclude that T cell-depleted allogeneic BMT poses a low risk for death due to GVHD, and should be considered for patients with relapsed and refractory indolent NHL.
logous stem cell support as salvage therapy. Despite this aggressive approach, relapse remains the primary cause of treatment failure and the majority of patients eventually succumb to their disease. Long-term disease-free survival is realized by approximately 40-50% of patients with intermediate-grade NHL with chemotherapy-sensitive relapse who undergo autologous bone marrow transplantation (BMT). 1, 2 In contrast, only 10-15% of patients with chemotherapy-resistant disease experience extended survival with most patients relapsing within the first year after treatment. 2 Previous pilot studies investigating the use of allogeneic BMT in the treatment of relapsed NHL have reported overall survival of 16-78% at 2 years. [3] [4] [5] [6] [7] Although there have been no randomized studies comparing autologous with allogeneic BMT for the treatment of relapsed NHL, there have been four comparative studies suggesting that allogeneic BMT improved progression-free survival without a corresponding benefit in overall survival because of the higher transplant-related mortality in the patients receiving allogeneic BMT. [8] [9] [10] [11] Patients with advanced stage indolent NHL who undergo autologous BMT with unmanipulated bone marrow as salvage therapy have an actuarial 5 year survival of approximately 40% but the probability of disease progression at 2 years is approximately 75%. [12] [13] [14] Allogeneic BMT has the intrinsic advantages of a tumorfree bone marrow and possibly a 'graft-versus-lymphoma' effect; however, it also carries the risk of death due to complications from graft-versus-host disease (GVHD). We have previously described a method of partial T cell depletion (1.7 log reduction) using the T 10 B 9 antibody that when used with an intensive preparative regimen results in less GVHD without increased graft failure. 15, 16 This report describes our experience using T cell-depleted allogeneic BMT for the treatment of patients with relapsed or refractory NHL.
Materials and methods
Thirty-seven consecutive patients with non-Hodgkin lymphoma underwent a T cell-depleted allogeneic bone marrow transplantation at the Medical College of Wisconsin between 1988 and 1996. All patients had relapsed or refractory NHL except two patients (UPN 181, 336) who underwent BMT in first complete remission. Patients underwent allogeneic BMT according to treatment protocols and informed consent procedures approved by the Institutional Review Committees on Human Investigations. Allogeneic bone marrow transplantation was used instead of autologous bone marrow or peripheral blood stem cell transplantation for the following reasons: bone marrow dysfunction from previous therapy, bone marrow involvement with lymphoma, and a diagnosis of lymphoblastic, or advanced indolent lymphoma. In addition, patients with chemotherapy refractory disease were offered allogeneic BMT. Patients must have been less than 65 years old.
The diagnoses were determined according to the Working Formulation and divided into indolent (WF A, B, C, D) and aggressive (WF E, F, G, H, I, J) types. 17 Patients with a diagnosis of transformed, follicular small cleaved lymphoma were analyzed with the indolent NHL group. Patients in complete remission (CR) had no clinically or radiographically detectable disease prior to transplantation. Partial response (PR) was defined as at least a 50% reduction in tumor bulk as measured by CT scanning or physical examination, sustained for 4 weeks after treatment with at least one cycle of standard-dose chemotherapy. Refractory disease was defined as less than a PR after chemotherapy. Patients were considered to have sensitive disease if they achieved a CR or PR after their last course of chemotherapy.
Conditioning regimen
All patients received a standard conditioning regimen consisting of intravenous cytarabine (3 g/m 2 every 12 h for six doses days Ϫ7, Ϫ6, Ϫ5, Ϫ4), cyclophosphamide (45 mg/kg given 6 h after the second and fourth doses of cytarabine, methylprednisolone (1 g/m 2 every 12 h for days Ϫ2, Ϫ1), and total body irradiation. 15 At the discretion of the attending physician, the cytarabine dose was reduced 25-50% for those patients over the age of 40 years. The TBI was begun 48 h after the last dose of cytarabine and was delivered at dose rates of 8-25 cGy/min in nine fractions over 3 days to a total of 14 Gy or six fractions over 3 days to a total of 13.2 Gy. Patients with bulky disease at the time of transplant received 650-1050 cGy to local fields delivered in fractionated doses over 3 days (usually on days Ϫ10, Ϫ9 and Ϫ8). Two patients received supplemental chemotherapy before the standard 7-day regimen: oral busulfan (4 mg/kg/day, days Ϫ9 and Ϫ8) in one patient (UPN 99) and another (UPN 190) received etoposide and doxorubicin.
All patients received GVHD prophylaxis consisting of T cell depletion of the donor marrow and cyclosporine as described previously. 15, 18 There is approximately a 1.7 Ϯ 0.4 log 10 depletion of functional T lymphocytes from the donor marrow. Cyclosporine was administered as an intravenous infusion beginning the day before the marrow infusion at 3 mg/kg per day and eventually changed to a corresponding oral dose when tolerated. In addition to T cell depletion and cyclosporine, the two patients transplanted with a haploidentical allograft also received antithymocyte globulin (20 mg/kg/day from day 7 to 21) and methylprednisolone (1 mg/kg/day from day 1 to 28).
Outcome measurements
Patients were assessed by imaging techniques at sites of prior disease and had repeat bone marrow biopsies at day 100 to determine the maximal response to BMT. Clinical and radiographic assessment was repeated approximately every 6 months for 2 years, and then yearly thereafter. Residual masses were not routinely biopsied, and were not considered to be persistent disease unless there was objective evidence of progression. Patients were considered evaluable for engraftment and acute GVHD if they survived more than 30 days post transplant. Acute and chronic GVHD was graded according to criteria set forth by Thomas et al. 19 Patients surviving at day 100 were considered evaluable for chronic GVHD. Kaplan-Meier survival estimates and confidence intervals were made using SPSS software (SPSS, Chicago, IL, USA). The analysis includes all patients who began the conditioning regimen.
PCR analysis
Samples of bone marrow and peripheral blood mononuclear cells were routinely collected and cryopreserved in all patients before and at various time-points after BMT. Nested PCR amplification at the major breakpoint region (MBR) and minor cluster region (mcr) of the BCL2/IgH translocation of t(14:18) were performed as previously described. 20, 21 Positive controls consisting of DHL-6 or DHL-16 cells admixed with 10 5 normal cells, were included and detected in each assay to ensure sensitive detection of the MBR and mcr. The cell lines DHL-6 and DHL-16, containing t(14;18) translocations at the MBR and mcr regions, respectively, were gifts from Dr A Epstein (University of Southern California, Los Angeles, CA, USA). The quality of each patient DNA sample was evaluated through amplification of a segment of the human growth hormone gene.
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Results
The patient and disease characteristics are summarized in Table 1 . The median age at the time of transplant was 43 (range 27-62) and 30 (range 6-48) years for patients with indolent and aggressive histologies, respectively. The median interval from diagnosis to transplant was 12 (range 5-419) months for those with indolent and 9 (range 2-165) months for patients with aggressive histologies, respectively. Histologically, 21 patients had aggressive, and 16 indolent disease. Of the total, 30 patients (81%) had received two or less chemotherapy regimens prior to BMT and 21 patients (56%) never achieved a CR. Twenty-six (70%) patients had a history of bone marrow involvement (15 of 16 with indolent disease) and 17 (46%) had chemotherapy refractory disease. Seven patients (19%) were in complete remission, 10 patients (27%) were in partial remission, and three patients (8%) were in first relapse at the time of BMT.
Marrow transplantation
The source of allogeneic bone marrow was a matched sibling in 24 patients (65%), partially matched family donor in seven patients (19%), matched unrelated donor in four (11%), and haploidentical family donor in two (5%). All patients were cared for in HEPA-filtered rooms and received irradiated blood products, broad-spectrum antibiotics, and total parenteral nutrition according to institutional guidelines.
Progression-free survival and causes of death
The outcome for the 37 patients is listed in Table 2 . Thirtytwo patients (86%) survived to day 30 and were evaluable for engraftment which occurred in 31 (97%). Four patients died of complications before day 30 (three of regimenrelated complications and one of infection). One patient died at day 31 of E. coli sepsis and Aspergillus pneumonia with continued pancytopenia. Sixteen of 37 patients are alive at a median of 53 months (range 10-124) post trans- plant. The 5 year overall probability of survival was 45% (95% confidence interval, 28-61%). Six of 21 patients with aggressive NHL (high and intermediate grade) are alive a median of 39 months after BMT; the 5 year probability of PFS is 33% (CI, 12-54%) (Figure 1) . Ten of 16 patients with low-grade NHL are alive a median of 70 months after BMT; the 5 year probability of PFS is 62% (CI, 37-86%) ( Figure 1 ). The 5 year probability of survival in patients with aggressive NHL with chemotherapy-resistant disease was 17% (CI, 0-47%) compared to 40% (CI, 15-65%) with sensitive disease (Figure 2 ). Among those with low-grade NHL, the 5 year probability of PFS was 55% (CI, 25-85%) and 80% (CI, 45-100%) for patients with chemotherapy resistant and sensitive disease respectively (Figure 3 ). Acute GVHD у grade II developed in 11 of 32 evaluable patients (34%) of whom two had grade III/IV. Seven patients with acute GVHD у grade II died, four from pro- RM = related matched; RPM = related partial matched; HAP = haploidentical; NR = non-related matched; LBL = lymphoblastic lymphoma; BL = Burkitt's lymphoma; DLC-I = diffuse large cell immunoblastic; DLC = diffuse large cell; FSM = follicular mixed cell; FSC = follicular small cleaved cell; SLL = small lymphocytic lymphoma; CR = complete remission; PR = partial remission; RL = relapse; RF = refractory; GVHD, graft-versus-host disease; NE = not evaluable; L = limited; E = extensive; CMV = cytomegalovirus.
gressive disease. No patient died directly from GVHD; however, two patients died from infections during treatment. Of the nine patients who did not develop acute GVHD, five died from progressive disease. Nine of 26 evaluable patients (35%) developed chronic GVHD which was extensive in three patients; one patient died.
The most common cause of death following BMT was regimen-related toxicity. Of the 21 deaths, 13 were due to regimen-related complications (infections in five, direct conditioning regimen toxicity in three, encephalopathy in three, interstitial pneumonia in one, and CNS bleed in one). The second most common cause of treatment failure was disease progression which occurred in eight patients. The actuarial probability of progression among patients with aggressive histologies was 43% (CI, 30-56%) and among patients with indolent NHL, 17% (CI, 6-28%) (Figure 4) .
PCR analysis
The pretransplant bone marrow from eight of 16 patients with indolent NHL contained a BCL2/IgH translocation detectable by PCR. The results of PCR on bone marrow collected from these patients at various times after BMT is depicted in Figure 5 . Of the eight patients, six were PCR positive at the last time-point tested and two were PCR negative. Four of the 6 PCR-positive patients are alive and progression-free after 761, 1293, 2369 and 2602 days; the other two died after relapse (at 339 and 485 days). Of the two patients who were PCR negative, one died early due to CMV pneumonia, and one is progression-free 2713 days after BMT.
Discussion
The role of allogeneic BMT in the treatment of NHL is currently unclear due to the limited number of studies comparing allogeneic BMT to autologous BMT or any other therapy. Most recently, Ratanatharathorn 11 reported the results of a non-randomized, comparative trial of allogeneic vs autologous BMT in 66 patients with relapsed aggressive NHL. Their approach favored allogeneic BMT if a suitable sibling donor was available thereby accomplishing a 'biological randomization'. Among patients with aggressive NHL (non-transformed indolent NHL was excluded), the clinical characteristics between the groups were comparable except that patients with BM involvement were excluded from autologous BMT. Allogeneic BMT resulted in a 71% lower relapse rate compared to autologous BMT although the difference in PFS (47 vs 24% at 14 months, respectively) was not significant due to the high allogeneic transplant-related mortality (30 vs 9%, respectively). Jones et al 9 in their retrospective analysis of 118 patients receiving allogeneic or autologous BMT for NHL (excluding indolent disease) found that allogeneic BMT was associated with a 61% reduction in relapse rate but again no significant difference in PFS (47% allogeneic vs 41% autologous at 4 years) due to the higher regimen-related mortality (47% vs 21%, respectively). Chopra et al 10 performed a retrospective case-controlled study comparing allogeneic vs autologous BMT among 202 patients with aggressive NHL. They found a significantly lower relapse rate among patients with lymphoblastic lymphoma who received an allogeneic rather than an autologous BMT (24 vs 48%, respectively) but the benefit did not extend to those with intermediate-grade NHL (29 vs 35%, respectively). Again there was no survival benefit. Finally, Appelbaum et al 8 in an early report described 90 patients who underwent autologous, allogeneic or syngeneic BMT for NHL. The high-risk patients in this study experienced a uniformly high relapse rate (75, 50 and 60%, respectively) and low PFS (16, 25 and 28%, respectively, at 2 years) and there was no benefit to allogeneic BMT. These non-randomized comparative trials have shown a 33-71% lower relapse rate among patients who have received allogeneic BMT, but the survival benefit is lost to regimen-related toxicity and complications from GVHD.
Allogeneic BMT avoids the infusion of viable tumor cells, and may provide an immune-mediated 'graft-versuslymphoma' effect. However, allogeneic BMT is associated with increased transplant-related mortality due to GVHD and complications of prolonged immune suppression. Whereas the use of T cell-depleted BMT reduces GVHD, a concern is whether relapse rates will suffer from loss of a possible 'graft-versus-lymphoma' effect. Our patients with aggressive NHL had an actuarial risk of relapse (43%) which is similar to previous reports using allogeneic BMT (18-50%). [9] [10] [11] Relapse remains a significant problem among patients with aggressive NHL, despite the use of allogeneic BMT.
In contrast, our patients with indolent NHL fared well after T cell-depleted allogeneic BMT with a plateau in the PFS of 61% after a median follow-up of almost 6 years. The risk of relapse among this group was low (17%) despite the fact that 11 of 16 had chemotherapy-resistant disease and most were heavily pre-treated. Our clinical experience with allogeneic BMT in patients with low-grade NHL is similar to that reported by van Besien et al 7, 23 who found a 59% PFS at 2 years among 15 patients with heavily treated or refractory low-grade NHL. Although their follow-up is somewhat shorter, the plateau of the PFS curve suggests the remissions may be durable. The t(14;18) breakpoint which characterizes follicular lymphomas can be amplified by PCR in approximately 75% of patients. 24 The BCL2/IgH translocation can be detected in the peripheral blood and bone marrow of patients with early-stage localized disease, 25, 26 and during first remissions of patients treated for advanced stage disease 27 reflecting the disseminated nature and persistence of the disease despite standard chemotherapy. We found the BCL2/IgH translocation by PCR in the bone marrow of eight patients before BMT and six remain positive. Despite the PCR results, four of the six patients remain progression-free after a median followup of 5.0 years (range 2.1-7.1 years). Allogeneic BMT appears promising for patients with low-grade NHL including those who harbor chemotherapy-refractory disease. This approach deserves greater consideration among younger patients with HLA-matched siblings.
